Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Cytochrome P450 3A4 (abbreviated CYP3A4) (EC 184.108.40.206), a member of the cytochrome P450 mixed-function oxidase system, is one of the most important enzymes involved in the metabolism of xenobiotics in the body. CYP3A4 is involved in the oxidation of the largest range of substrates of all the CYPs. CYP3A4 is also, correspondingly, present in the largest quantity of all the CYPs in the liver.
Although CYP3A4 is predominantly found in the liver, it is also present in other organs and tissues of the body where it may play an important role in metabolism. CYP3A4 in the intestine plays an important role in the metabolism of certain drugs. Often this allows prodrugs to be activated and absorbed - as in the case of the histamine H1-receptor antagonist terfenadine.
While over 28 single nucleotide polymorphisms (SNPs) have been identified in the CYP3A4 gene, it has been found that this does not translate into significant interindividual variability in vivo. It can be supposed that this may be due to the induction of CYP3A4 on exposure to substrates.
Variability in CYP3A4 function can be determined noninvasively by the erythromycin breath test (ERMBT). The ERMBT estimates in vivo CYP3A4 activity by measuring the radiolabelled carbon dioxide exhaled after an intravenous dose of (14C-N-methyl)-erythromycin.
CYP3A4 is induced by a wide variety of ligands. These ligands bind to the Pregnane X Receptor (PXR). The activated PXR complex forms a heterodimer with the Retinoid X Receptor (RXR) which binds to the XREM region of the CYP3A4 gene. XREM is a regulatory region of the CYP3A4 gene, and binding causes a cooperative interaction with proximal promoter regions of the gene, resulting in increased transcription and expression of CYP3A4.
- See also: List of drugs affected by grapefruit
- ↑ Robertson G, Field J, Goodwin B, Bierach S, Tran M, Lehnert A, Liddle C (2003). Transgenic mouse models of human CYP3A4 gene regulation. Mol Pharmacol 64 (1): 42–50.
- ↑ Watkins P (1994). Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4 (4): 171–84.
- ↑ Where classes of agents are listed, there may be exceptions within the class
- ↑ 4.0 4.1 Mentioned both in the reference named FASS and were previously mentioned in Wikipedia. Further contributions may follow other systems
- ↑ Swedish environmental classification of pharmaceuticals Facts for prescribers (Fakta för förskrivare)
- ↑ 6.0 6.1 6.2 Flockhart DA (2007). Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. Retrieved on December 25, 2008.
- ↑ 7.0 7.1 Non-nucleoside reverse transcriptase inhibitors have been shown to both induce and inhibit CYP3A4.
- REDIRECT Template:Dioxygenases
Cytochromes, oxygenases: cytochrome P450 (EC 1.14)
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|